Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus

J Antimicrob Chemother. 1995 Jun;35(6):865-8. doi: 10.1093/jac/35.6.865.

Abstract

Arbekacin (1-N-((S)-4-amino-2-hydroxybutyryl)-3',4'-dideoxykanamycin B) was active against 54 strains of methicillin-resistant Staphylococcus aureus from 16 different countries, all of which were resistant to > or = 32 mg/L amikacin. MICs of arbekacin ranged from 1 to 16 mg/L, the MIC50 was 3.2 mg/L and the mode geometric mean MICs were 4 and 4.5 mg/L respectively.

MeSH terms

  • Aminoglycosides*
  • Anti-Bacterial Agents*
  • Dibekacin / analogs & derivatives*
  • Dibekacin / pharmacology
  • Kanamycin / analogs & derivatives*
  • Kanamycin / pharmacology
  • Methicillin Resistance*
  • Microbial Sensitivity Tests
  • Staphylococcus aureus / drug effects*

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • bekanamycin
  • Dibekacin
  • Kanamycin
  • arbekacin